Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) EBT Margin (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EBT Margin for 15 consecutive years, with 316.61% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin fell 6461.0% to 316.61% in Q3 2025 year-over-year; TTM through Sep 2025 was 264.74%, a 1267.0% decrease, with the full-year FY2024 number at 250.7%, up 2033.0% from a year prior.
  • EBT Margin was 316.61% for Q3 2025 at Plus Therapeutics, down from 108.71% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1847.0% in Q3 2021 to a low of 7149.32% in Q3 2022.
  • A 5-year average of 787.52% and a median of 276.42% in 2024 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: plummeted -899632bps in 2022, then soared 688107bps in 2023.
  • Plus Therapeutics' EBT Margin stood at 1847.0% in 2021, then plummeted by -341bps to 4446.46% in 2022, then soared by 93bps to 292.76% in 2023, then rose by 6bps to 276.42% in 2024, then fell by -15bps to 316.61% in 2025.
  • Per Business Quant, the three most recent readings for PSTV's EBT Margin are 316.61% (Q3 2025), 108.71% (Q2 2025), and 385.55% (Q1 2025).